MDXH

MDxHealth S.A. (MDXH) Risks & Opportunities Analysis (2026)

Invetso Score: 3.4/10 — Weak · Last Updated: 2026-09-01

Overall Score

Liquidity Solvency Risk

Current ratio is only 1.08 and quick ratio is 0.94, leaving limited near-term liquidity cushion.

Cash ratio of 0.59 suggests the company is not highly cash-rich relative to short-term obligations.

Negative solvency ratio and high debt-to-assets ratio of 0.64 indicate a stretched balance sheet.

Profitability Cash Flow Risk

TTM EBITDA margin is -7.3% and operating margin is -16.6%, showing ongoing operating losses.

Free cash flow yield is negative and operating cash flow is negative, indicating weak cash generation.

Return on assets is -17.7% and return on invested capital is -12.7%, reflecting poor capital efficiency.

Valuation Dilution Risk

EV/Sales of 1.26 is not demanding on revenue alone, but it is offset by negative earnings and cash flow.

Price-to-book is negative because book value per share is negative, limiting balance-sheet support for valuation.

No dividend is being paid, so shareholders are relying entirely on operational turnaround for returns.

Operating Efficiency Risk

Gross margin remains relatively healthy at 57.7%, but it is not translating into positive operating profit.

Days sales outstanding of 65.9 and cash conversion cycle of 27.8 days suggest working-capital management is acceptable but not enough to offset losses.

SG&A at 40.7% of revenue remains heavy relative to the company’s revenue base.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on MDxHealth S.A.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →